ADC Capacity Updates
-
Simplifying ADC Development Through CDMO Collaboration
6/17/2026
Two CDMOs are working together to simplify ADC development. Learn how integrated support and collaboration can reduce complexity, streamline transfers, and keep programs moving forward.
-
Abzena Capabilities Update June 2026: ADC
6/16/2026
Antibody-Oligonucleotide Conjugates expand targeted gene modulation. Overcoming manufacturing, annealing, and loading-ratio challenges requires advanced bioconjugation and robust orthogonal analytics.
-
Abzena Capacity Update October 2025: ADC
10/15/2025
Explore ThioBridge™ as an efficient site-specific conjugation technology to generate ADCs and other conjugate modalities, such as AOCs and conjugates for diagnostic applications.
-
Simtra BioPharma Solutions Capacity Update October 2025: ADC
8/7/2025
MilliporeSigma and Simtra's streamlined collaboration encompasses every stage, including bioconjugation, linker and payload supplies, formulation development, and final fill/finish of drug substance.
-
MilliporeSigma Capacity Update October 2025: ADC
7/28/2025
MilliporeSigma and Simtra's streamlined collaboration encompasses every stage, including bioconjugation, linker and payload supplies, formulation development, and final fill/finish of drug substance.
-
Integrated ADC Offering: From Concept To Commercialization
7/28/2025
Leveraging deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.